PHCEF - PharmaCielo Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
3.5560
-0.0840 (-2.31%)
At close: 3:56PM EDT
Stock chart is not supported by your current browser
Previous Close3.6400
Open3.6376
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range3.5000 - 3.6376
52 Week Range3.0460 - 9.9750
Volume15,903
Avg. Volume50,181
Market Cap343.415M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PharmaCielo Announces Financial Results for the Second Quarter 2019
    CNW Group

    PharmaCielo Announces Financial Results for the Second Quarter 2019

    PharmaCielo Announces Financial Results for the Second Quarter 2019

  • PharmaCielo's Very First Commercial CBD Export from Colombia Lands in Europe
    CNW Group

    PharmaCielo's Very First Commercial CBD Export from Colombia Lands in Europe

    TORONTO and CHAM, Switzerland , Aug. 19, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., confirmed today it successfully completed the first commercial export of CBD isolate to Europe . The inaugural shipment of the high quality CBD isolate, a key ingredient in various cannabis derived therapeutic, nutraceutical, topicals and lifestyle products, was delivered to the Swiss headquarters of Creso Pharma, a global pharmaceutical with expertise in cannabis- and hemp-derived products for human and veterinarian use. This comes on the heels of the Colombian government granting the first commercial CBD isolate exporting permit to PharmaCielo, as announced on July 25, 2019 .

  • Benzinga

    PharmaCielo Announces Expansion In Latin America Through Veterinary CBD Partnership

    Canada-based PharmaCielo Ltd (OTC: PHCEF ), one of the largest cannabis companies operating in Colombia, announced this week it's teaming up with Uruguay-based Laboratorios Adler to supply the latter with ...

  • PharmaCielo Expands Further Into Latin America With Sales Agreement to Supply CBD Extracts, Oils and Veterinary Products to Laboratorios Adler
    CNW Group

    PharmaCielo Expands Further Into Latin America With Sales Agreement to Supply CBD Extracts, Oils and Veterinary Products to Laboratorios Adler

    TORONTO and MONTEVIDEO, Uruguay , Aug. 13, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced it has signed a sales agreement with Uruguay -based Laboratorios Adler ("Adler"). According to the agreement, PharmaCielo will provide Adler with bulk CBD extracts, bulk and bottled CBD oils and veterinary products that will be sold by Adler in Uruguay , Paraguay , Bolivia and Southern Brazil .

  • PharmaCielo Joins Canadian Market Cannabis Tracking and Verification Initiative
    CNW Group

    PharmaCielo Joins Canadian Market Cannabis Tracking and Verification Initiative

    TORONTO and RIONEGRO, Colombia , Aug. 8, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced it has joined the TruTrace Technologies, Inc. ("TruTrace") (CSE:TTT, OTCQB:TTTSF) and Shoppers Drug Mart initiated medical cannabis pilot verification program ("Pilot Program").

  • PharmaCielo Colombia Holdings S.A.S. Appoints New and Diversified Board of Directors
    CNW Group

    PharmaCielo Colombia Holdings S.A.S. Appoints New and Diversified Board of Directors

    PharmaCielo Colombia Holdings S.A.S. Appoints New and Diversified Board of Directors

  • PharmaCielo Achieves Twelvefold Increase in Dried Cannabis Processing Capacity to Meet Global Demand for Medicinal Oil Extracts
    CNW Group

    PharmaCielo Achieves Twelvefold Increase in Dried Cannabis Processing Capacity to Meet Global Demand for Medicinal Oil Extracts

    TORONTO and RIONEGRO, Colombia , Aug. 1, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO, OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is ramping up its oil processing capabilities in the Company's Rionegro, Colombia facility following the recent acquisition and installation of additional high-performance, high-volume extractors, combined with proprietary extraction techniques.

  • Benzinga

    The Cannabis Sustainability Inquiry: Could Marijuana And Hemp Offer The Solution To The World's Toughest Environmental, Social, And Economic Problems?

    As a nascent (legal) consumer industry, the cannabis industry has a chance to invent itself from the ground up in the image of modern-day social, economic, and environmental sustainability. In March 2020 the United Nations is set to vote on what may be the termination of a half-Century of Treaty ban on Cannabis medicines. The World Health Organization is actively in the process of unprecedented scientific assessment of Cannabis, cannabinoids and Cannabis derivatives to begin to separate global stigma of the plant from the potential, its truly untapped medicinal, health-oriented public benefits.

  • PharmaCielo Completes Acquisition of Ubiquo Telemedicina
    CNW Group

    PharmaCielo Completes Acquisition of Ubiquo Telemedicina

    TORONTO , July 26, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced that it has completed the acquisition of all of the shares (the "Acquisition") of Ubiquo Telemedicina S.A.S. ("Ubiquo Telemedicina"), previously announced on April 20, 2018 .

  • PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate
    CNW Group

    PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate

    PharmaCielo First to Receive Colombian Government Export Approval for Commercial Sale of CBD Isolate

  • PharmaCielo Colombia Holdings S.A.S. Appoints Andres Felipe Botero as Chief Operations Officer
    CNW Group

    PharmaCielo Colombia Holdings S.A.S. Appoints Andres Felipe Botero as Chief Operations Officer

    RIONEGRO, Colombia , July 22, 2019 /CNW/ - PharmaCielo Colombia Holdings S.A.S. ("PharmaCielo Colombia" or the "Company"), the premier cultivator and producer of medicinal-grade cannabis oils and extracts in Colombia and subsidiary of Canadian firm PharmaCielo Ltd. (TSXV:PCLO, OTC:PHCEF), is pleased to announce the appointment of Andres Felipe Botero as Chief Operations Officer (COO).

  • Benzinga

    From Coffee To Cannabis: Colombia's Choice Between Economic Development And 'CannaMercantilism'

    This is the second of a two-part series on the history of Colombia’s troubled past and how it has informed its route to cannabis legalization. Mr. Azadian replied, “We were frustrated with many things in the marketplace including product inconsistency, quality control standards, inefficiencies, high costs of products and environmentally unsustainable operations.

  • PharmaCielo Announces Trading on the OTC Market
    CNW Group

    PharmaCielo Announces Trading on the OTC Market

    TORONTO and RIONEGRO, Colombia , June 21, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO) (OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is pleased to announce that it is trading on the OTC Markets under the symbol "PHCEF". "With our recently announced acquisition agreement with Creso Pharma (CPH.AX) there is increased attention and interest in our stock. Trading on the OTC will increase access for U.S. and international investors, providing greater liquidity and better access to capital. As we move forward building a global medicinal cannabis company, we will work to provide easy access and liquidity for investors in all jurisdictions," said David Attard , Chief Executive Officer of PharmaCielo Ltd.

  • PharmaCielo to Acquire International Cannabis Company Creso Pharma for A$122 Million
    CNW Group

    PharmaCielo to Acquire International Cannabis Company Creso Pharma for A$122 Million

    TORONTO , June 6, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced that it has entered into a scheme implementation agreement (the "Implementation Agreement") pursuant to which PharmaCielo has agreed to acquire all of the issued and outstanding shares and listed options of Creso Pharma Ltd. ("Creso Pharma") (CPH.AX), for an aggregate purchase price of approximately A$122 million (the "Acquisition").  Creso Pharma is a global medicinal cannabis company that specializes in research, development and production of therapeutic, nutraceutical and animal health products. PharmaCielo will pay A$0.63 per Creso Pharma share, representing a premium of 50% over the closing trading price of the Creso Pharma shares on May 31 , 2019.

  • PharmaCielo Gears Up for U.S. Market Demand, Enlists Former Congressman and Medical Cannabis Advocate Dana Rohrabacher as a Special Advisor
    PR Newswire

    PharmaCielo Gears Up for U.S. Market Demand, Enlists Former Congressman and Medical Cannabis Advocate Dana Rohrabacher as a Special Advisor

    TORONTO, May 29, 2019 /PRNewswire/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that it has enlisted former U.S. congressman and long-time medical cannabis advocate Dana Rohrabacher as a special advisor to the Company.

  • PharmaCielo Announces its Financial Results for the Fourth Quarter and Fiscal Year 2018
    CNW Group

    PharmaCielo Announces its Financial Results for the Fourth Quarter and Fiscal Year 2018

    PharmaCielo expects to begin commercial sales in 2019. Oil processing facility is on track for commercial operation and GMP certification during Q3-2019, enabling large-scale production and sale of refined cannabis oil. Currently, 10 hectares are under active cultivation, expanding to 20 hectares (~2.15 million square feet) by year-end 2019, backed by 20 proprietary registered strains and 186 strains in the Company's germplasm bank.

  • CNW Group

    PharmaCielo Doubles Its Portfolio of Proprietary Cannabis Strains Approved for Colombia's Cultivar Registration

    TORONTO and RIONEGRO, COLOMBIA , March 29, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that its Colombian subsidiary has received from the national cultivar registry approval for the listing of a further 10 strains, each of which has a prominent tetrahydrocannabinol (THC) profile. The additional registration of the new strains to the national cultivar registry, including a unique 1:1 THC to CBD ratio strain, doubles the number of approved strains PharmaCielo holds in the registry, making it the largest holder of approved strains in Colombia .